JS207
JS207 is a humanized IgG4-specific antibody targeting PD-1 and VEGFA. JS207 can block PD-1/PD-L1, PD-1/PD-L2, and VEGFA/VEGFR2 interactions, with IC50 values of 6.37 nM, 4.3 nM, and 3.35 nM, respectively. JS207 can relieve immunosuppression, promote T cell activation and IL-2/IFN-γ release, and induce PD-1 internalization. JS207 can inhibit VEGF-driven angiogenesis and has the property that VEGFA enhances PD-1 internalization. JS207 cross-reacts with cynomolgus monkey PD-1/VEGFA and rat/mouse VEGFA, but does not bind rat/mouse PD-1. JS207 shows antitumor efficacy in mouse colon cancer and melanoma models. JS207 can be used for research related to colon cancer and melanoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
VEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
Species Reactivity
Human
体外実験
JS207 cross-reacts with human and cynomolgus monkey PD-1 as well as human, cynomolgus monkey, rat, and mouse VEGFA[1].
JS207 (2 μg/mL) binds human PD-1 with a KD of 0.46 nM[1].
JS207 (30 nM; 0.5-4 h) induced PD-1 internalization in H293/PD-1 cells, reaching up to 65% in the presence of VEGFA[1].
JS207 (15 pM-150 nM; 5 days) promotes IL-2 and IFN-γ release in the MLR assay[1].
JS207 binds human VEGFA with a KD of 9 pM[1].
JS207 inhibits VEGFA/VEGFR2 signaling in the H293/VEGFR2 reporter gene assay with an IC50 of 0.773 nM[1].
JS207 (0.005-10 nM; 96 h) inhibits VEGFA-induced HUVEC proliferation with an IC50 of 0.296 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
JS207 (1.0-10.0 mg/kg; intraperitoneal injection; twice weekly; 6 doses total) produced dose-dependent tumor growth inhibition in the A375 melanoma NDG mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6-Pdcd1tm1(PDCD1)Bcgen/Bcgen (B-hPD-1 humanized mice)[1]
-
Dosage:0.75 mg/kg, 1.5 mg/kg, and 4.5 mg/kg
-
Administration:intraperitoneally; twice weekly; for 6 doses
-
Result:Significantly inhibited tumor growth dose-dependently at 0.75, 1.5, and 4.5 mg/kg, achieving tumor growth inhibition (TGI) rates of 76.1%, 78.0%, and 84.4%, respectively, at day 20.
-
Animal Model:NDG mice were implanted subcutaneously with A375 cells at 5×106 cells/mouse suspended and mixed with Matrigel[1]
-
Dosage:1.0 mg/kg, 3.0 mg/kg, and 10.0 mg/kg
-
Administration:intraperitoneally; twice weekly; for 6 doses
-
Result:In the saline group, the mean tumor volume reached 585 mm3 at day 21.
At 1, 3, and 10 mg/kg, mean tumor volumes were 362 mm3, 344 mm3, and 262 mm3, corresponding to TGI rates of 49.6%, 53.7%, and 72.0%, respectively.
Target
PD-1 & VEGF
Conjugated
Unconjugated
アプリケーション
ELISA, FACS, Functional assay
化学情報
-
SMILES
[JS207]
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
JS207 関連分類
HY-P992548 関連分類
Powered by Bioz